Jupiter Wellness’ Merger Partner Next Frontier Pharmaceuticals, Inc. Announces Plans for Oral Dronabinol Solution for the Treatment of Alzheimer’s Disease Agitation

Next Frontier Pharmaceuticals is pursuing FDA 505(b)(2) fast-track approval with its previously FDA approved oral dronabinol (THC) solution Next Frontier Pharmaceuticals has completed a pre-IND meeting with the FDA, and intends to commence Phase II Clinical Trials in the 2H 2022; industry research and studies support targeted efficacy endpoints Alzheimer’s Disease Agitation (Agit-AD) is estimated […]

Investor Alerts

Get our news

For up-to-date company news delivered straight to your inbox or phone, sign up for Investor Alerts today.

To receive alerts via text message, send JUPW to
 +1 (844) 819-8138